These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 39105620)

  • 1. TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.
    Lazarevic V; Lilljebjörn H; Olsson-Arvidsson L; Orsmark-Pietras C; Ågerstam H
    Genes Chromosomes Cancer; 2024 Aug; 63(8):e23261. PubMed ID: 39105620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
    Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
    Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
    Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
    Schwaab J; Knut M; Haferlach C; Metzgeroth G; Horny HP; Chase A; Tapper W; Score J; Waghorn K; Naumann N; Jawhar M; Fabarius A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2015 Feb; 94(2):233-8. PubMed ID: 25260694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained Response to Ruxolitinib of Eosinophilia-Associated Myeloproliferative Neoplasm with Translocation t(8;9)(p21;p24).
    Cai P; Liu S; Duan L; Huo L; Wu D; Chen S; Yang R; Yang X
    Acta Haematol; 2023; 146(5):397-400. PubMed ID: 37562364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.
    Chase A; Bryant C; Score J; Haferlach C; Grossmann V; Schwaab J; Hofmann WK; Reiter A; Cross NC
    Haematologica; 2013 Mar; 98(3):404-8. PubMed ID: 22875628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.
    Kaplan HG; Jin R; Bifulco CB; Scanlan JM; Corwin DR
    Oncologist; 2022 Aug; 27(8):e661-e670. PubMed ID: 35472244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
    Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
    Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
    [No Abstract]   [Full Text] [Related]  

  • 10. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
    Chen JA; Hou Y; Roskin KM; Arber DA; Bangs CD; Baughn LB; Cherry AM; Ewalt MD; Fire AZ; Fresard L; Kearney HM; Montgomery SB; Ohgami RS; Pearce KE; Pitel BA; Merker JD; Gotlib J
    Blood Adv; 2021 Sep; 5(17):3492-3496. PubMed ID: 34505882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Shao H; Wang W; Song J; Tang G; Zhang X; Tang Z; Srivastava J; Shah B; Medeiros LJ; Zhang L
    Leuk Res; 2020 Dec; 99():106460. PubMed ID: 33166908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report].
    Song Y; Zhang YR; Han Y; Wang Y; Li YQ; Chai Y; Zeng PY; Yue LL; Wu CY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):690. PubMed ID: 34547879
    [No Abstract]   [Full Text] [Related]  

  • 15. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
    Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
    Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature.
    Schoelinck J; Gervasoni J; Guillermin Y; Beillard E; Pissaloux D; Chassagne-Clement C
    Virchows Arch; 2024 May; 484(5):853-857. PubMed ID: 37985498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.
    Snider JS; Znoyko I; Lindsey KG; Morse J; Baughn LB; Hoppman NL; Pitel BA; Pearce KE; Schandl CA; Wolff DJ
    Cancer Genet; 2020 Aug; 246-247():44-47. PubMed ID: 32827877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.
    Reiter A; Walz C; Watmore A; Schoch C; Blau I; Schlegelberger B; Berger U; Telford N; Aruliah S; Yin JA; Vanstraelen D; Barker HF; Taylor PC; O'Driscoll A; Benedetti F; Rudolph C; Kolb HJ; Hochhaus A; Hehlmann R; Chase A; Cross NC
    Cancer Res; 2005 Apr; 65(7):2662-7. PubMed ID: 15805263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
    Patterer V; Schnittger S; Kern W; Haferlach T; Haferlach C
    Ann Hematol; 2013 Jun; 92(6):759-69. PubMed ID: 23400675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.